Evidence map›Paper›PMID 34412904›Full record

SynthesisArchives of medical research2022

Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.

Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L Chen, Mubashir Ayaz Ahmed, Keun Young Kim and 6 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Archives of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tiantian HanDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Anhui Province, China.
Shaodi MaDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Anhui Province, China.
Chenyu SunInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA. Electronic address: drsunchenyu@yeah.net.
Huimei ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Anhui Province, China.
Guangbo QuDepartment of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Anhui Province, China.
Yue ChenDepartment of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, Hefei, Anhui Province, China.
Ce ChengThe University of Arizona College of Medicine at South Campus, Tucson, AZ, USA.
Eric L ChenInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA.
Mubashir Ayaz AhmedInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA.
Keun Young KimInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA.
Raveena ManemInternal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA.
Mengshi ChenHunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, Hunan Province, China.
Zhichun GuoMassachusetts college of Pharmacy and Health sciences, Boston, MA, USA.
Hongru YangMassachusetts college of Pharmacy and Health sciences, Boston, MA, USA.
Yue YanMassachusetts college of Pharmacy and Health sciences, Boston, MA, USA.
Qin ZhouDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsDuring the current Coronavirus Disease 2019 (COVID-19) pandemic, patients with diabetes face disproportionately more. This study was performed to clarify anti-inflammatory effects of anti-diabetic agents on COVID-19 in patients with diabetes. METHODS AND

resultsRelevant literature was searched on 15 databases up to November 14, 2020 and was updated on April 13, 2021. The pooled ORs along with 95% CIs were calculated to evaluate combined effects. 31 studies with 66,914 patients were included in qualitative and quantitative synthesis. Meta-analysis showed that metformin was associated with a statistically significant lower mortality (pooled OR = 0.62, 95% CI, 0.50-0.76, p = 0.000) and poor composite outcomes (pooled OR = 0.83, 95% CI, 0.71-0.97, p = 0.022) in diabetic patients with COVID-19. Significance of slight lower mortality remained in sulfonylurea/glinides (pooled OR = 0.93, 95% CI, 0.89-0.98, p = 0.004), but of poor composite outcomes was not (pooled OR = 1.48, 95% CI, 0.61-3.60, p = 0.384). Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) were associated with statistically non-significant lower mortality (pooled OR = 0.95, 95% CI, 0.72-1.26, p = 0.739) or poor composite outcomes (pooled OR = 1.27, 95% CI, 0.91-1.77, p = 0.162) of COVID-19 in diabetic patients.

conclusionMetformin might be beneficial in decreasing mortality and poor composite outcomes in diabetic patients infected with SARS-CoV-2. DPP-4 inhibitors, sulfonylurea/glinides, SGLT-2 inhibitors, and GLP-1RA would not seem to be adverse. There was insufficient evidence to conclude effects of other anti-diabetic agents. Limited by retrospective characteristics, with relative weak capability to verify causality, more prospective studies, especially RCTs are needed. REGISTRATION NUMBER: PROSPERO-CRD42020221951.

Indexed as

COVID-19 Drug TreatmentDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHumansHypoglycemic AgentsProspective StudiesRetrospective StudiesSARS-CoV-2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsAnti-diabetic agentsDiabetesDPP-4 inhibitors COVID-19Meta-analysisMetformin

Identifiers

PMID34412904
PMCPMC8349690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.